In Brief: ImmuLogic
Executive Summary
ImmuLogic: Modifies Allervax CAT development program to include "at least one additional trial prior to a PLA submission," company says following meeting with FDA on Dec. 19. A Phase III trial evaluating a 750 mcg dose of Allervax CAT (peptide immunotherapeutic for treatment of allergies to cat dander) administered twice a week for two weeks is set to begin in the second quarter of 1997. That trial will focus on more severely allergic patients...